Floatz logo

ANDROSTANE-3,17-DIOL, 16-(1-METHYL-1-PIPERIDINIUMYL)-2-(1-PIPERIDINYL)-, DIACETATE (ESTER), (2.BETA.,3.ALPHA.,5.ALPHA.,16.BETA.,17.BETA.)-

Uterine Neoplasms

Yuri Semenyuk Rivne Regional Clinical HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Uterine Neoplasms cohort.

Asset / SponsorPhaseRating
FULVESTRANT
Atavistik Bio, Inc
Phase 2B
Docetaxel
Montefiore Medical Center
Phase 2B
Hycamtin
Montefiore Medical Center
Phase 2B
TRASTUZUMAB
Seagen, a wholly owned subsidiary of Pfizer
Phase 2CCC
Tucatinib
Seagen, a wholly owned subsidiary of Pfizer
Phase 2CCC

View all 12 →

Same molecule, other indications

ANDROSTANE-3,17-DIOL, 16-(1-METHYL-1-PIPERIDINIUMYL)-2-(1-PIPERIDINYL)-, DIACETATE (ESTER), (2.BETA.,3.ALPHA.,5.ALPHA.,16.BETA.,17.BETA.)- is also rated in:

neuromuscular junction diseaseDormant
BB
Indicative ·
69 / 100
View asset →
StrokeDormant
B
Indicative ·
58 / 100
View asset →
Uterine FibroidsDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →